CA2609376A1 - Construction lipidique pour l'administration d'interferon a un mammifere - Google Patents

Construction lipidique pour l'administration d'interferon a un mammifere Download PDF

Info

Publication number
CA2609376A1
CA2609376A1 CA002609376A CA2609376A CA2609376A1 CA 2609376 A1 CA2609376 A1 CA 2609376A1 CA 002609376 A CA002609376 A CA 002609376A CA 2609376 A CA2609376 A CA 2609376A CA 2609376 A1 CA2609376 A1 CA 2609376A1
Authority
CA
Canada
Prior art keywords
interferon
lipid
construct
alpha
biotin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002609376A
Other languages
English (en)
Inventor
John R. Lau
W. Blair Geho
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SDG Technology Inc
Original Assignee
Sdg, Inc.
John R. Lau
W. Blair Geho
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/384,575 external-priority patent/US20070218117A1/en
Application filed by Sdg, Inc., John R. Lau, W. Blair Geho filed Critical Sdg, Inc.
Publication of CA2609376A1 publication Critical patent/CA2609376A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dispersion Chemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA002609376A 2005-05-23 2006-05-16 Construction lipidique pour l'administration d'interferon a un mammifere Abandoned CA2609376A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US68387805P 2005-05-23 2005-05-23
US60/683,878 2005-05-23
US11/384,575 US20070218117A1 (en) 2006-03-20 2006-03-20 Supra molecular construct for delivery of interferon to a mammal
US11/384,575 2006-03-20
PCT/US2006/019118 WO2006127360A2 (fr) 2005-05-23 2006-05-16 Construction lipidique pour l'administration d'interferon a un mammifere

Publications (1)

Publication Number Publication Date
CA2609376A1 true CA2609376A1 (fr) 2006-11-30

Family

ID=37452604

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002609376A Abandoned CA2609376A1 (fr) 2005-05-23 2006-05-16 Construction lipidique pour l'administration d'interferon a un mammifere

Country Status (6)

Country Link
EP (1) EP1883395A4 (fr)
JP (1) JP2008542270A (fr)
KR (1) KR20080042045A (fr)
AU (1) AU2006249479A1 (fr)
CA (1) CA2609376A1 (fr)
WO (1) WO2006127360A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100254942A1 (en) * 2007-08-03 2010-10-07 Biotron Limited Hepatitis c antiviral compositions and methods
US8962015B2 (en) * 2007-09-28 2015-02-24 Sdg, Inc. Orally bioavailable lipid-based constructs
CA2709550A1 (fr) * 2007-12-17 2009-06-25 Lux Innovate Limited Compositions et methodes de systemes d'acheminement et de confinement de fluides
EP2916859B1 (fr) 2012-11-02 2017-06-28 The U.S.A. as represented by the Secretary, Department of Health and Human Services Méthode de réduction des effets secondaires chez un patient souffrant de cancer traité par un inhibiteur de la mek
CN111690539A (zh) * 2020-07-07 2020-09-22 安徽农业大学 高效秸秆纤维素分解菌的筛选及应用
GB2616223A (en) * 2020-11-27 2023-08-30 D&D Pharmatech Inc Oral formulation of biologically active material conjugate having biotin moiety, fatty acid moiety, or combination thereof coupled thereto
EP4252780A1 (fr) * 2020-11-27 2023-10-04 D&D Pharmatech Inc. Conjugué de matériau biologiquement actif ayant une fraction biotine, un fraction d'acide gras, ou une combinaison de celles-ci couplées à celui-ci

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603044A (en) * 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
GB9426484D0 (en) * 1994-12-08 1995-03-08 Ciba Geigy Ag Compositions
TW520297B (en) * 1996-10-11 2003-02-11 Sequus Pharm Inc Fusogenic liposome composition and method

Also Published As

Publication number Publication date
KR20080042045A (ko) 2008-05-14
AU2006249479A1 (en) 2006-11-30
EP1883395A4 (fr) 2012-07-04
WO2006127360A2 (fr) 2006-11-30
JP2008542270A (ja) 2008-11-27
EP1883395A2 (fr) 2008-02-06
WO2006127360A3 (fr) 2008-01-10

Similar Documents

Publication Publication Date Title
DK2859015T3 (en) LIGANDS MODIFIED BY CIRCULAR MODIFICATION AS AGONISTS AND ANTAGONISTS
EP3391876B1 (fr) Construction lipidique pour administration d'insuline à un mammifère
US10463616B2 (en) Lipid construct for delivery of insulin to a mammal
US8257735B2 (en) Method of increasing the bioavailability of recombinant human insulin isophane in a patient
EP2205217B1 (fr) Structures à base lipidique et à biodisponibilité orale
CA2609376A1 (fr) Construction lipidique pour l'administration d'interferon a un mammifere
US7871641B2 (en) Hepatocyte-targeting vehicle for delivery of glargine insulin to a mammal
US20070218117A1 (en) Supra molecular construct for delivery of interferon to a mammal
EP2552202B1 (fr) Procédés et compositions pour la perte de poids
JP2014221794A (ja) ペプチドおよびタンパク質の薬学的因子の精製および安定化
CA2515892A1 (fr) Vehicule d'administration de medicament lipophile et methodes d'utilisation correspondantes
US20100129428A1 (en) Supra molecular construct for delivery of interferon to a mammal
US20220110870A1 (en) Lipid construct for delivery of insulin to a mammal
AU2012247063B2 (en) Lipid construct for delivery of insulin to a mammal
CA2864366C (fr) Construction de lipide comportant un lipide amphipathique, du cholesterol, du dicetyl phosphate et un recepteur hepatocyte liant une molecule
DK1883394T3 (en) Lipid construct for delivering insulin to a mammal
EP1146890B1 (fr) Systeme d'administration orale de medicaments proteiniques
JPH01238537A (ja) 肝障害治療剤
JP2023533797A (ja) 脂質複合体を含む経口医薬組成物
CN114870000A (zh) 用于线粒体靶向治疗的两亲性前药及其纳米颗粒的制备方法和应用

Legal Events

Date Code Title Description
FZDE Discontinued